Related coverage linked through entity extraction aliases.
Apr 30, 2026
In TRIDENT, GMRx2 reduced recurrent stroke risk by 39% after intracerebral hemorrhage. LT3001 was safe in phase 2 acute ischemic stroke trials, supporting a global phase 3.
Jun 26, 2026
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
Mar 23, 2026
BridgeBio Pharma will present interim analysis data from its Phase 3 FORTIFY trial of BBP-418 for limb-girdle muscular dystrophy at the 2026 MDA conference. The study has met efficacy endpoints, with additional presentations planned from academic collaborators. The company previously announced its Q4 and full year 2025 financial results release date.
Feb 21, 2026
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
Feb 18, 2026
OncoHost announced publication of a study in JPBA introducing a computational framework that harmonizes serum and plasma proteomic datasets, enabling researchers to combine previously incompatible specimen types for biomarker research.
